Repligen Corp.

RSS Feed
Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. The company's bioprocessing business is comprised of: Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and OEM products, which are represented by its Protein A affinity ligands and cell culture growth factor products
  • TickerRGEN
  • ISINUS7599161095
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
GlobeNewsWire

Repligen to Report First Quarter 2021 Financial Results

Repligen to Report First Quarter 2021 Financial Results Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.The conference call will be accessible by dia...

Free
Corporate Voice
Health Care
Repligen Corp.
23d 20/04/2021 1 EN
TheScreener

REPLIGEN sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of REPLIGEN (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date March 5, 2021, the closing price was USD 186.19 and its target price was estimated at USD 159.06.

EUR 12.42
Quant
Health Care
Repligen Corp.
68d 06/03/2021 6 EN
GlobeNewsWire

Repligen Corporation to Present at Barclays Global Healthcare Conference

Repligen Corporation to Present at Barclays Global Healthcare Conference WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  section of the Company’s website, and will be available for replay ...

Free
Corporate Voice
Health Care
Repligen Corp.
71d 03/03/2021 1 EN
GlobeNewsWire

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growthOrganic revenue growth was 47% for the fourth quarter and 29% for the year 2020 WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights...

Free
Corporate Voice
Health Care
Repligen Corp.
78d 24/02/2021 1 EN
GlobeNewsWire

Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference

Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST. A live webcast of the discussion will be accessible through the  section of the Company’s website...

Free
Corporate Voice
Health Care
Repligen Corp.
80d 22/02/2021 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

EUR 207.03
Chart
Technology
ACMR , ADTN ...
1y 28/04/2020 55 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Technology
AMD , AEM. ...
1y 27/04/2020 39 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Chart
Technology
VNET , ACAD ...
1y 24/04/2020 42 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

EUR 207.03
Chart
Construction & Materials
AAON , AKAM ...
1y 17/03/2020 62 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

EUR 207.03
Chart
Technology
VNET , AAON ...
1y 17/03/2020 62 EN
GlobeNewsWire

Repligen to Report First Quarter 2021 Financial Results

Repligen to Report First Quarter 2021 Financial Results Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.The conference call will be accessible by dia...

Free
Corporate Voice
Health Care
Repligen Corp.
23d 20/04/2021 1 EN
GlobeNewsWire

Repligen Corporation to Present at Barclays Global Healthcare Conference

Repligen Corporation to Present at Barclays Global Healthcare Conference WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  section of the Company’s website, and will be available for replay ...

Free
Corporate Voice
Health Care
Repligen Corp.
71d 03/03/2021 1 EN
GlobeNewsWire

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growthOrganic revenue growth was 47% for the fourth quarter and 29% for the year 2020 WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highlights...

Free
Corporate Voice
Health Care
Repligen Corp.
78d 24/02/2021 1 EN
GlobeNewsWire

Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference

Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST. A live webcast of the discussion will be accessible through the  section of the Company’s website...

Free
Corporate Voice
Health Care
Repligen Corp.
80d 22/02/2021 1 EN
GlobeNewsWire

Repligen to Report Fourth Quarter and Full Year 2020 Financial Results

Repligen to Report Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. ESTWALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended Dece...

Free
Corporate Voice
Health Care
Repligen Corp.
90d 11/02/2021 1 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.41
Equity
Chemicals
ALB , ALTM ...
188d 06/11/2020 27 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.41
Equity
Technology
AMD , AGCO ...
286d 31/07/2020 26 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 41.41
Equity
Retail
AAP , AXL ...
1y 18/05/2020 22 EN
Vermilion Research
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

EUR 41.41
Equity
Retail
TWOU , ABMD ...
1y 13/05/2020 43 EN
TheScreener

REPLIGEN sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of REPLIGEN (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date March 5, 2021, the closing price was USD 186.19 and its target price was estimated at USD 159.06.

EUR 12.42
Quant
Health Care
Repligen Corp.
68d 06/03/2021 6 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch